# A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> clinical trial · VERIFIED · 2026-08-26

Status: RECRUITING · Sponsor: BeOne Medicines · Condition: Chronic Lymphocytic Leukemia

- Company: BeOne Medicines
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06973187

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.